Disount To Net Cash For A Promising CAR-T Company
Galapagos NV’s split could unlock value despite short-term share decline. Learn why GLPG stock’s strategic focus offers ...
'Health equity is a business imperative:' Companies work for better Black health outcomes
At the State of Black Health second annual summit hosted by BlackDoctor.org in partnership with USA TODAY, corporate leaders ...
FiercePharma8d
Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch
With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Gilead Sciences Inc. closed 1.35% below its 52-week high of $106.69, which the company achieved on February 14th.
Deutsche upgrades Gilead to Buy on ability to offset patent cliffs
Deutsche Bank upgraded Gilead (GILD) to Buy from Hold with a price target of $120, up from $80. The company’s core HIV treatment franchise ...
Why Gilead Sciences Stock Is Jumping Today
Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...
Gilead Sciences: Strong Q4 Results And Huge Progress In HIV
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...
Gilead announces FDA acceptance of lenacapavir NDA submissions
Gilead (GILD) announced that the FDA has accepted its new drug application submissions for lenacapavir, the company’s twice-yearly injectable ...
CSR Wire16h
The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune Disease
Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives ...